Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne ...Middle East

--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was...

Hence then, the article about ascletis announces completion of 180 patient enrollment for phase ii clinical trial of fasn inhibitor asc40 for acne was published today ( Wednesday 30/11/2022 - 03:40 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne )

Also on site :

• Pedestrian killed on 101 Freeway in Calabasas-Agoura Hills area
• Certis and FieldAI Form Strategic Partnership to Deploy Autonomous Robotics in Real-World Security Operations
• Peter Mandelson arrest latest: Peer released on bail as Epstein accuser Virginia Giuffre’s family issues statement